Questions: Pharmaceutical Quality and Purity Analysis

Question 1

An analyst detects a synthetic intermediate at 0.12% in a drug product taken at a daily dose of 1 g. According to ICH Q3A thresholds, what action is required?

• A. No action is needed — 0.12% is below all reporting thresholds
• B. The impurity must be reported and structurally identified
• C. The impurity must only be reported, not identified
• D. The impurity must be reported, identified, and qualified for safety

Answer: (B)

For a 1 g/day drug, the ICH Q3A identification threshold is 0.10% — any impurity above this level must be structurally characterized. At 0.12%, the impurity exceeds the identification threshold but not the qualification threshold (0.15% for a 2 g/day drug; similar thresholds apply here), so structural identification is required but a full safety qualification study is not yet triggered. Option D would apply if the level were above the qualification threshold.

Question 2

A USP monograph specifies a particular C18 column, mobile phase, and detection wavelength for a drug assay. A laboratory wants to use a slightly different column from a different manufacturer. What must they do?

• A. Nothing — column brand does not affect the validity of a USP method
• B. Document the change in a lab notebook and proceed
• C. Formally demonstrate method equivalence through validation before using the alternative column
• D. Obtain permission from the drug manufacturer before any changes

Answer: (C)

USP monographs are legally enforceable standards, not guidelines. A laboratory may use an alternative system only if they can formally demonstrate equivalence — meaning the alternative column produces results within the same acceptance criteria as the specified method. This requires validation data showing equivalent selectivity, accuracy, and precision. Simply assuming a column of the same type from a different vendor will perform identically is not acceptable in a regulated pharmaceutical quality control laboratory.

Question 3

Accelerated stability testing at 40°C/75% relative humidity is used to predict long-term shelf life more quickly than waiting for real-time data.

• T. True
• F. False

Answer: True

Accelerated stability conditions (40°C/75% RH) stress the drug product to speed up degradation kinetics, allowing prediction of long-term behavior in months rather than years. These results are used to support early approval timelines and set preliminary shelf-life estimates while real-time data at 25°C/60% RH accumulates. The two datasets together establish the approved shelf life and storage conditions.

Question 4

The 95–105% of label claim acceptance criterion for API content applies universally to most pharmaceutical dosage forms.

• T. True
• F. False

Answer: False

While 95–105% is a common range for solid oral dosage forms, acceptance criteria are set individually in each pharmacopeial monograph and regulatory submission. Narrow therapeutic index drugs (e.g., anticoagulants, thyroid hormones) may have tighter specifications (e.g., 90–110% or even narrower), while some biologics or modified-release products have different acceptance windows. The criterion is product-specific, not universal.

Question 5

Why are ICH impurity reporting, identification, and qualification thresholds expressed relative to daily dose rather than simply as a fixed percentage of the drug product?

Model answer: Because the actual amount of impurity a patient is exposed to depends on how much drug they take. A 0.1% impurity in a 10 mg/day drug delivers 0.01 mg/day, while the same 0.1% in a 2 g/day drug delivers 2 mg/day — a 200-fold difference in exposure. Dose-based thresholds ensure that the safety evaluation is proportional to actual human exposure rather than to an arbitrary percentage that would be permissive for high-dose drugs and overly strict for low-dose drugs.

This dose-normalization principle underlies the entire ICH Q3A/Q3B framework. It reflects the toxicological reality that risk is driven by exposure (amount × duration), not by relative concentration alone. A substance that is safe at microgram per day exposures may be hazardous at milligram levels, so the threshold for requiring safety qualification must scale with the total amount reaching the patient.